Local drug delivery in recurrent malignant gliomas

A. Boiardi, M. Eoli, A. Salmaggi, E. Lamperti, A. Botturi, A. Solari, F. Di Meco, G. Broggi, A. Silvani

Research output: Contribution to journalArticlepeer-review


In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.

Original languageEnglish
JournalNeurological Sciences
Issue numberSUPPL. 1
Publication statusPublished - May 2005


  • Doxorubicine
  • Glioblastoma
  • Loco-regional chemotherapy
  • Nimustine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Local drug delivery in recurrent malignant gliomas'. Together they form a unique fingerprint.

Cite this